Alex. Thanks,
the Looking growth year-over-year franchise, growth. quarter, am back with continued XX% than Emflaza quarter, our greater excluding I at had in strong Brazil. with proud the performance year-over-year, of commercial XX% second Duchenne nearly an outstanding
to environment key our commercial hear in As global our platforms due challenging will throughout PTC you the programs the has the the pipeline. and of advanced execute despite pandemic, remainder and business in continued call,
small validated molecule is platform. of One platforms these key our splicing
it generate innovation be spinal PDUFA atrophy, for first most old cannot that target be approaching. August platform advanced which When SMA date commercial has all our over function Risdiplam represents our or The believe can and how substantial is biology, that which Because understanding for we stakeholders. be our treatment actually was mechanism the is know, competitive the program expertise SMA that were selectively considered you with a splicing with validates be treatment program for splicing was the of we will time dominant modulated structures decade and RNAs most rare small product molecules. a a principle. risdiplam that the is that shot. unique splicing many at that belief was most only in devastating We value It RNA SMA XX, can for is deep to first the the rapidly all knew on catalytic with great the risdiplam a muscular and of the potential targeted. loon with in this started disorder. occurs RNAs and a can splicing of As enzyme ago, form
would targeting We multiple knew RNA represents for to that lead also discover could successful new patients a discovery. lead new options It for with rare to platform living that drug new paradigm a disorders. to the compounds treatment
novel platform. built the technology risdiplam the a to of the Over led splicing discovery have into years, that we
unique RNA recently platform splicing in we has biology. highlighted As dive, in PTC our deep expertise
to integrated We process clinic, optimized proven in infrastructure global proprietary have therapies centric compound and isle bring to constructed bring patients. them to library, screening to tools, a compounds an disorder rare the a the fully commercial
number in dive, you this slicing the expected compound to next PTCXXX, development is next year. candidates targets this later human be development for X X has As enter years. platform additional X to on clinic to moving candidate is forward. to our is have Huntington’s first disease, heard The X deep which a trial over of We a a may that splicing the anticipate our recent
from emerging In exciting [indiscernible]. new are our pipeline, there to Huntington’s programs splicing disease, including addition deep
in platforms progress making the other programs also quarter. and in are second We
We a to expands of the inborn PTCXXX program the our have platform treatment patients. best-in-class addition errors capabilities for pipeline acquisition be our the PKU through PKU. has with believe the it potential late-stage for for PTCXXX of of strengthened metabolism. We
worked trial activity the The quickly in We a and for the PTCXXX mechanism against is with PTCXXX two rapidly We antiviral Phase being COVID-XX. COVID-XX. SARS-CoV-X effective moving into for leading is conducted infection. PTCXXX clinical both for of has academic initiated trial We also confirm recently collaborators clinic against that stages in vitro viral stages. X/X the potentially that dual recognized unique
anticipate first X both expect to line for of reporting in in Phase We completed results be and XXXX. the of half stages top XXXX half second the
States, have confidence We Ultimately, and initiate additional United the months. of the countries in it’s the well-established oral preclinical combination profile, the a Australia, with great in and Spain to the coming COVID-XX. multiple Brazil, bioavailability us for safety sites in mechanism, a potentially data, that treatment the as gives expected compound’s PTCXXX
took we to COVID-XX because global industry forward pandemic towards solution. PTCXXX our requires One our work of reasons is that the
to its of on COVID-XX our obvious our early to many operations. we At steps including has PTC, our potential addition In and individuals, risks the own. took effect aggressive industries, health impacted to mitigate
others. the key despite COVID-XX, on we have execute by challenges been to certain programs and presented the impact lessen Importantly, able on
vatiquinone, this the mentioned PTCXXX Phase trials this two late expect I for Huntington’s platform, first-in-human X initiate known registrational PTCXXX track In earlier, year. later for our Bio-e year. trial to potential to remain formerly on for we as As disease a initiate
to excited as disorders opportunities the rare provide We need. they are near-term these trials about for significant unmet medical particularly us with address two upcoming
compound PTCXXX, Phase ahead of as X schedule. addition, for a we platform initiated In we recently Bio-e the second from our announced, study
I and the over first for Translarna the developments pass mutation muscular to Duchenne developed team, dystrophy, by call touch with nonsense want we to the on product discovered, I PTC. Before recent commercialized
to our statement, not profile which Translarna to on patients. outside make of the revision non-ambulatory renewals to has of approval, for the reimbursement professionals recommended the The also ambulation. with discussions Translarna removing with This conditional Translarna on healthcare patients of use States. treatments been continuing CHMP Translarna Importantly, enables recently took non-ambulatory. lost the judgment the benefit clinical have basis six decisions our the their EMA become risk the further authorities demonstrated is label supports who treatment who annual their patients for sales United efficacy It change in
for therapies dystrophy Duchenne pioneered the clinical Matt? highly key call have and over for updates Matt remain now We the muscular will programs. turn committed I on our to to community.
